Historical Valuation
Summit Therapeutics Inc (SMMT) is now in the Fair zone, suggesting that its current forward PS ratio of 171.83 is considered Fairly compared with the five-year average of -20.97. The fair price of Summit Therapeutics Inc (SMMT) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：19.68
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Summit Therapeutics Inc (SMMT) has a current Price-to-Book (P/B) ratio of 67.84. Compared to its 3-year average P/B ratio of 40.56 , the current P/B ratio is approximately 67.26% higher. Relative to its 5-year average P/B ratio of 25.88, the current P/B ratio is about 162.08% higher. Summit Therapeutics Inc (SMMT) has a Forward Free Cash Flow (FCF) yield of approximately -2.00%. Compared to its 3-year average FCF yield of -2.36%, the current FCF yield is approximately -15.11% lower. Relative to its 5-year average FCF yield of -11.68% , the current FCF yield is about -82.89% lower.
P/B
Median3y
40.56
Median5y
25.88
FCF Yield
Median3y
-2.36
Median5y
-11.68
Competitors Valuation Multiple
AI Analysis for SMMT
The average P/S ratio for SMMT competitors is 34.77, providing a benchmark for relative valuation. Summit Therapeutics Inc Corp (SMMT.O) exhibits a P/S ratio of 171.83, which is 394.17% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for SMMT
1Y
3Y
5Y
Market capitalization of SMMT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SMMT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is SMMT currently overvalued or undervalued?
Summit Therapeutics Inc (SMMT) is now in the Fair zone, suggesting that its current forward PS ratio of 171.83 is considered Fairly compared with the five-year average of -20.97. The fair price of Summit Therapeutics Inc (SMMT) is between to according to relative valuation methord.
What is Summit Therapeutics Inc (SMMT) fair value?
SMMT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Summit Therapeutics Inc (SMMT) is between to according to relative valuation methord.
How does SMMT's valuation metrics compare to the industry average?
The average P/S ratio for SMMT's competitors is 34.77, providing a benchmark for relative valuation. Summit Therapeutics Inc Corp (SMMT) exhibits a P/S ratio of 171.83, which is 394.17% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Summit Therapeutics Inc (SMMT) as of Jan 10 2026?
As of Jan 10 2026, Summit Therapeutics Inc (SMMT) has a P/B ratio of 67.84. This indicates that the market values SMMT at 67.84 times its book value.
What is the current FCF Yield for Summit Therapeutics Inc (SMMT) as of Jan 10 2026?
As of Jan 10 2026, Summit Therapeutics Inc (SMMT) has a FCF Yield of -2.00%. This means that for every dollar of Summit Therapeutics Inc’s market capitalization, the company generates -2.00 cents in free cash flow.
What is the current Forward P/E ratio for Summit Therapeutics Inc (SMMT) as of Jan 10 2026?
As of Jan 10 2026, Summit Therapeutics Inc (SMMT) has a Forward P/E ratio of -51.56. This means the market is willing to pay $-51.56 for every dollar of Summit Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Summit Therapeutics Inc (SMMT) as of Jan 10 2026?
As of Jan 10 2026, Summit Therapeutics Inc (SMMT) has a Forward P/S ratio of 171.83. This means the market is valuing SMMT at $171.83 for every dollar of expected revenue over the next 12 months.